Literature DB >> 12755957

Surgical treatment of medullary thyroid carcinoma.

M S Cohen1, J F Moley.   

Abstract

Medullary thyroid carcinoma (MTC) is a malignancy of the parafollicular C cells of the thyroid gland. It occurs sporadically or as part of the multiple endocrine neoplasia type 2 (MEN 2) syndromes. Patients who have inherited a mutation in the RET proto-oncogene should have thyroidectomy early in life to prevent formation and spread of this cancer. Most patients with sporadic disease present with a palpable neck mass. The diagnosis is made by fine needle aspiration biopsy and by measuring calcitonin levels in the blood. Primary treatment consists of surgical resection including a total thyroidectomy, central neck nodal dissection and functional lateral neck nodal dissections. Most patients with a palpable primary tumour have nodal disease present at the time of operation, and nodal involvement is often bilateral. Adequate resection of the primary tumour and cervical lymph nodes is important to optimize outcome and minimize the risk of recurrent disease. Proper handling of the parathyroid glands prevents hypoparathyroidism. Following primary surgical resection, more than half of the patients will have recurrent disease with persistent elevation of calcitonin levels. Currently, there is no adequate systemic therapy for treating recurrent disease. Surgical reoperation or conservative observation are the best available options. Diagnostic laparoscopy for liver evaluation is the most sensitive diagnostic test to detect the presence of distant metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755957     DOI: 10.1046/j.1365-2796.2003.01166.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  21 in total

1.  Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.

Authors:  M F Erdogan; A Gürsoy; G Ozgen; M Cakir; F Bayram; R Ersoy; E Algün; B Cetinarslan; A Cömlekçi; P Kadioglu; M K Balci; I Yetkin; T Kabalak; G Erdogan
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 2.  Parathyroid hormone-dependent hypercalcemia.

Authors:  Judit Toke; Attila Patócs; Katalin Balogh; Péter Gergics; Balázs Stenczer; Károly Rácz; Miklós Tóth
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

4.  Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: Long-term follow-up.

Authors:  Shi Hong Ma; Qin Jiang Liu; You Cheng Zhang; Rong Yang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

5.  Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases.

Authors:  Christian Scheuba; Klaus Kaserer; Klaus Kaczirek; Reza Asari; Bruno Niederle
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

6.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

Authors:  Joseph E Ippolito; Jian Xu; Sanjay Jain; Krista Moulder; Steven Mennerick; Jan R Crowley; R Reid Townsend; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

Review 7.  Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment.

Authors:  Shabina R Ahmed; Douglas W Ball
Journal:  J Clin Endocrinol Metab       Date:  2011-02-23       Impact factor: 5.958

8.  Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.

Authors:  Abbas K Samadi; Joseph Bazzill; Xuan Zhang; Rob Gallagher; Hauping Zhang; Rao Gollapudi; Kelly Kindscher; Barbara Timmermann; Mark S Cohen
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

Review 9.  10 rare tumors that warrant a genetics referral.

Authors:  Kimberly C Banks; Jessica J Moline; Monica L Marvin; Anna C Newlin; Kristen J Vogel
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

10.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.